All questions
Safety: Ocrevus (ocrelizumab) in multiple sclerosis 17 questions · 7 sources
Questions that apply to every indication of Ocrevus are on Ocrevus (ocrelizumab), all indications .
Monitoring What tests are needed before starting Ocrevus or Ocrevus Zunovo? How long are patients monitored after an Ocrevus or Ocrevus Zunovo dose? Side effects How common are infusion reactions with Ocrevus IV? Applies to Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS intravenous)
“Symptoms of infusion reactions can include pruritus, rash, urticaria, erythema, bronchospasm, throat irritation, oropharyngeal pain, dyspnea, pharyngeal or laryngeal edema, flushing, hypotension, pyrexia, fatigue, headache, dizziness, nausea, tachycardia, and anaphylaxis. These reactions are more commonly reported with the first infusion.” (opens the source at this quote in a new tab) Copy Flag
Note: The rates are from Tables 4 (RMS, OPERA I and II) and 5 (PPMS, ORATORIO) of the OCREVUS Prescribing Information. REBIF-treated patients received placebo infusions every 24 weeks, and the PPMS comparator was placebo infusions.
How common are injection reactions with Ocrevus Zunovo? Applies to Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)
“In Study 4, injection reactions occurred in 49% (58/118) of patients after the first injection of OCREVUS
ZUNOVO. Of these 118 patients, 47% and 11% experienced at least one local injection reaction and one systemic
injection reaction, respectively. The most common symptoms reported by patients with local and systemic
injection reactions included: injection site erythema, injection site pain, injection site swelling, injection site
pruritus, headache, and nausea. Among the patients experiencing an injection reaction, the majority of patients
(83%) had injection reactions occur within 24 hours after the end of the injection, as opposed to during the
injection (19%). All injection reactions were of mild (73%) or moderate (27%) severity. The median duration of
symptoms was 3 days for systemic injection reactions and 3.5 days for local injection reactions. All patients
recovered from injection reactions, of which 26% required symptomatic treatment.
For subsequent injections, among the 118 patients who received OCREVUS ZUNOVO only throughout the study,
the frequency of local injection reactions ranged from 31% to 43% and the frequency of systemic injection
reactions ranged from 3% to 7% from Injection 2 to Injection 4. All injection reactions were of mild or moderate
severity.” (opens the source at this quote in a new tab) Copy Flag
Note: Study 4 of the OCREVUS ZUNOVO Prescribing Information is OCARINA II, an open-label trial.
How are Ocrevus infusion reactions and Ocrevus Zunovo injection reactions managed? What are the most common side effects of Ocrevus? Applies to Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS intravenous)
Note: The rates are from Tables 4 (RMS, OPERA I and II, OCREVUS vs REBIF) and 5 (PPMS, ORATORIO, OCREVUS vs placebo) of the OCREVUS Prescribing Information, which list adverse reactions with an incidence of at least 5% for OCREVUS and higher than the comparator.
Do people develop antibodies against Ocrevus? Applies to Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS intravenous)
Note: Studies 1, 2, and 3 of the OCREVUS Prescribing Information are OPERA I, OPERA II, and ORATORIO.
Warnings Does Ocrevus increase the risk of infections? “Serious, including life-threatening or fatal, bacterial, viral, parasitic and fungal infections have been reported in patients receiving ocrelizumab. An increased risk of infections (including serious and fatal bacterial, fungal, and new or reactivated viral infections) has been observed in patients during and following completion of treatment with anti-CD20 B-cell depleting therapies.
A higher proportion of adult patients treated with OCREVUS experienced infections compared to patients taking REBIF or placebo. In RMS trials in adults, 58% of patients treated with OCREVUS experienced one or more infections compared to 52% of patients treated with REBIF. In the PPMS trial, 70% of patients treated with OCREVUS experienced one or more infections compared to 68% of patients on placebo. Ocrelizumab increases the risk for upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes-related infections.” (opens the source at this quote in a new tab) Copy Flag
Note: The all-exposure population includes patients from the controlled trials, their open-label extensions, and other ocrelizumab studies.
Does Ocrevus increase the risk of herpes or shingles? “In active-controlled (RMS) clinical trials in adults, herpes infections were reported more frequently in patients treated with OCREVUS than in patients treated with REBIF, including herpes zoster (2.1% vs. 1.0%), herpes simplex (0.7% vs. 0.1%), oral herpes (3.0% vs. 2.2%), genital herpes (0.1% vs. 0%), and herpes virus infection (0.1% vs. 0%). Infections were predominantly mild to moderate in severity. In the placebo-controlled (PPMS) clinical trial, oral herpes was reported more frequently in the patients treated with OCREVUS than in the patients on placebo (2.7% vs. 0.8%).
Serious cases of infections caused by herpes simplex virus and varicella zoster virus, including central nervous system infections (encephalitis and meningitis), intraocular infections, and disseminated skin and soft tissue infections, have been reported in the postmarketing setting in multiple sclerosis patients receiving ocrelizumab. Serious herpes virus infections may occur at any time during treatment with ocrelizumab. Some cases were life-threatening.
If serious herpes infections occur, treatment with ocrelizumab should be discontinued or withheld until the infection has resolved, and appropriate treatment should be administered.” (opens the source at this quote in a new tab) Copy Flag
Is hepatitis B screening required before Ocrevus or Ocrevus Zunovo? Can Ocrevus cause progressive multifocal leukoencephalopathy (PML)? “Cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients with MS treated with ocrelizumab in the postmarketing setting. PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in patients who are immunocompromised, and that usually leads to death or severe disability. PML has occurred in ocrelizumab-treated patients who had not been treated previously with natalizumab, (which has a known association with PML), were not taking any immunosuppressive or immunomodulatory medications associated with risk of PML prior to or concomitantly with ocrelizumab and did not have any known ongoing systemic medical conditions resulting in compromised immune system function.
JCV infection resulting in PML has also been observed in patients treated with other anti-CD20 antibodies and other MS therapies.
At the first sign or symptom suggestive of PML, withhold treatment with ocrelizumab-containing products and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.
Magnetic resonance imaging (MRI) findings may be apparent before clinical signs or symptoms of PML. Monitoring with MRI for signs consistent with PML may be useful, and any suspicious findings should lead to further investigation to allow for an early diagnosis of PML, if present. If PML is confirmed, treatment with ocrelizumab should be discontinued.” (opens the source at this quote in a new tab) Copy Flag
Does Ocrevus lower immunoglobulin (IgG) levels? “In the active-controlled (RMS) trials (Study 1 and Study 2), the proportion of patients at baseline reporting IgG,
IgA, and IgM below the lower limit of normal (LLN) in OCREVUS-treated patients was 0.5%, 1.5%, and 0.1%,
respectively. Following treatment, the proportion of OCREVUS-treated patients reporting IgG, IgA, and IgM
below the LLN at 96 weeks was 1.5%, 2.4%, and 16.5%, respectively.
In the placebo-controlled (PPMS) trial (Study 3), the proportion of patients at baseline reporting IgG, IgA, and
IgM below the LLN in OCREVUS-treated patients was 0.0%, 0.2%, and 0.2%, respectively. Following
treatment, the proportion of OCREVUS-treated patients reporting IgG, IgA, and IgM below the LLN at 120
weeks was 1.1%, 0.5%, and 15.5%, respectively.” (opens the source at this quote in a new tab) Copy Flag
Does Ocrevus increase the risk of cancer, including breast cancer? Note: The all-exposure population includes patients from the controlled trials, their open-label extensions, and other ocrelizumab studies.
Can people taking Ocrevus get vaccines, including live vaccines? Can Ocrevus cause colitis? Can Ocrevus cause liver damage? “Clinically significant liver injury, without findings of viral hepatitis, has been reported in the postmarketing setting in patients treated with anti-CD20 B-cell depleting therapies approved for the treatment of MS, including ocrelizumab. Signs of liver injury, including markedly elevated serum hepatic enzymes with elevated total bilirubin, have occurred from weeks to months after administration.
Patients treated with ocrelizumab found to have an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3x the upper limit of normal (ULN) with serum total bilirubin greater than 2x ULN are potentially at risk for severe drug-induced liver injury.
Obtain liver function tests prior to initiating treatment with ocrelizumab, and monitor for signs and symptoms of any hepatic injury during treatment. Measure serum aminotransferases, alkaline phosphatase, and bilirubin levels promptly in patients who report symptoms that may indicate liver injury, including new or worsening fatigue, anorexia, nausea, vomiting, right upper abdominal discomfort, dark urine, or jaundice. If liver injury is present and an alternative etiology is not identified, discontinue ocrelizumab.” (opens the source at this quote in a new tab) Copy Flag
Who should not take Ocrevus (contraindications)?